Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.
J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. PMID: 16896006 [PubMed - indexed for MEDLINE]Related articles